MX2023004725A - Antagonistas bifuncionales del factor de necrosis tumoral alfa y del factor de crecimiento transformante beta y usos de los mismos. - Google Patents
Antagonistas bifuncionales del factor de necrosis tumoral alfa y del factor de crecimiento transformante beta y usos de los mismos.Info
- Publication number
- MX2023004725A MX2023004725A MX2023004725A MX2023004725A MX2023004725A MX 2023004725 A MX2023004725 A MX 2023004725A MX 2023004725 A MX2023004725 A MX 2023004725A MX 2023004725 A MX2023004725 A MX 2023004725A MX 2023004725 A MX2023004725 A MX 2023004725A
- Authority
- MX
- Mexico
- Prior art keywords
- bifunctional
- antagonists
- beta
- alpha
- tgf
- Prior art date
Links
- 230000001588 bifunctional effect Effects 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 title 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 title 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 title 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1
- 230000001404 mediated effect Effects 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000019491 signal transduction Effects 0.000 abstract 2
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 abstract 1
- 102000057208 Smad2 Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La exposición de esta invención proporciona nuevos polipéptidos antagonistas bifuncionales que comprenden al menos un dominio de unión a TNF-a y al menos un dominio de unión a TGF-ß, que son altamente capaces de secuestrar TNF-a y TGF-ß en paralelo. También se proporcionan composiciones farmacéuticas de tales antagonistas polipeptídicos bifunciona1es y sus usos para tratar varias enfermedades complejas, cuya patogenia implica la activación de la vía de señalización de NF-kB mediada por TNF-a y la vía de señalización de Smad2/3 mediada por TGF-ß.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063104850P | 2020-10-23 | 2020-10-23 | |
| PCT/US2021/056282 WO2022087435A1 (en) | 2020-10-23 | 2021-10-22 | Bifunctional antagonists of tumor necrosis factor-alpha and transforming growth factor-beta and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004725A true MX2023004725A (es) | 2024-02-23 |
Family
ID=81290113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004725A MX2023004725A (es) | 2020-10-23 | 2021-10-22 | Antagonistas bifuncionales del factor de necrosis tumoral alfa y del factor de crecimiento transformante beta y usos de los mismos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230391892A1 (es) |
| EP (1) | EP4232063A1 (es) |
| JP (1) | JP2023546759A (es) |
| KR (1) | KR20230112629A (es) |
| CN (1) | CN116744959A (es) |
| AU (1) | AU2021365528A1 (es) |
| CA (1) | CA3196077A1 (es) |
| MX (1) | MX2023004725A (es) |
| WO (1) | WO2022087435A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2976359T (lt) * | 2013-03-20 | 2018-12-27 | Genzyme Corporation | Nebaigtinės osteogenezės gydymo būdai |
| KR101787003B1 (ko) * | 2014-06-13 | 2017-10-18 | 애피바디 에이비 | 신규한 폴리펩티드 |
| MX364040B (es) * | 2016-11-11 | 2019-04-11 | Cell Therapy And Tech S A De C V | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). |
| CA3093078A1 (en) * | 2018-03-06 | 2019-09-12 | The Trustees Of The University Of Pennsylvania | Prostate-specific membrane antigen cars and methods of use thereof |
| GB201903767D0 (en) * | 2019-03-19 | 2019-05-01 | Quadrucept Bio Ltd | Multimers, tetramers & octamers |
-
2021
- 2021-10-22 CA CA3196077A patent/CA3196077A1/en active Pending
- 2021-10-22 US US18/033,337 patent/US20230391892A1/en active Pending
- 2021-10-22 CN CN202180086722.1A patent/CN116744959A/zh active Pending
- 2021-10-22 MX MX2023004725A patent/MX2023004725A/es unknown
- 2021-10-22 AU AU2021365528A patent/AU2021365528A1/en active Pending
- 2021-10-22 JP JP2023549958A patent/JP2023546759A/ja active Pending
- 2021-10-22 KR KR1020237017317A patent/KR20230112629A/ko unknown
- 2021-10-22 EP EP21884002.3A patent/EP4232063A1/en active Pending
- 2021-10-22 WO PCT/US2021/056282 patent/WO2022087435A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| US20230391892A1 (en) | 2023-12-07 |
| JP2023546759A (ja) | 2023-11-07 |
| CA3196077A1 (en) | 2022-04-28 |
| EP4232063A1 (en) | 2023-08-30 |
| WO2022087435A1 (en) | 2022-04-28 |
| AU2021365528A1 (en) | 2023-06-15 |
| KR20230112629A (ko) | 2023-07-27 |
| CN116744959A (zh) | 2023-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA520412268B1 (ar) | EphA2 مركبات ترابطية من ببتيدات ثنائية الحلقة خاصة بـ | |
| NZ756763A (en) | Engineered transferrin receptor binding polypeptides | |
| EP3949969A3 (en) | Benzazepine compounds, conjugates, and uses thereof | |
| EA201992590A1 (ru) | Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения | |
| BR112018008011A2 (pt) | proteínas de ligação triespecíficas e/ou trivalentes para prevenção ou tratamento de infecção por hiv | |
| EA201100546A1 (ru) | Полипептиды, вариабельные домены антител и антагонисты | |
| EG25544A (en) | Solid redispersible emulsion | |
| EA200702656A1 (ru) | Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение | |
| EA200801343A1 (ru) | Иммуноглобулины, направленные против nogo | |
| MX2020009857A (es) | Conjugados de interleucina-2 (il-2). | |
| EP4372002A3 (en) | Proximity-based sortase-mediated protein purification and ligation | |
| MX2022013453A (es) | Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas. | |
| AR113422A2 (es) | Agentes tensioactivos reconstituidos que tienen propiedades mejoradas | |
| NZ759601A (en) | Aggrecan binding immunoglobulins | |
| WO2010030395A3 (en) | Withaferin a analogs and uses thereof | |
| ZA202211667B (en) | Multispecific heavy chain antibodies with modified heavy chain constant regions | |
| MX2019014448A (es) | Inmunoglobulinas de enlace a mmp13. | |
| DE10193689D2 (de) | Retardpartikeldispersion | |
| MX2021006989A (es) | Ligandos peptidicos biciclicos especificos para metaloproteasa tipo 1 de membrana (mt1-mmp). | |
| WO2021024133A3 (en) | Biopharmacuetical compositions and related methods | |
| MX2023004724A (es) | Antagonistas bifuncionales de la activina y del factor alfa de necrosis tumoral y usos de los mismos. | |
| MX2023004725A (es) | Antagonistas bifuncionales del factor de necrosis tumoral alfa y del factor de crecimiento transformante beta y usos de los mismos. | |
| WO2007034490A3 (en) | Diastereomeric peptides for modulating t cell immunity | |
| MX2023005693A (es) | Anticuerpos de cadena pesada que se unen al receptor de folato alfa. | |
| MX2023001466A (es) | Enlazadores de base peptidica. |